Min S, Helissey P, Callais F, Giorgi-Renault S, Festy B
Laboratoire d'Hygiène et de Santé Publique, CNRS URA 1310, Faculté Sciences Pharmaceutiques et Biologiques, Paris, France.
Mutat Res. 1992 Oct;280(4):225-31. doi: 10.1016/0165-1218(92)90052-2.
A series of seven 6-methylindolo[3,2-c]quinoline-1,4-diones substituted either in the 2 position or in 3 position by various groups were examined for their ability to induce mutation in the Ames test at several concentrations in four strains of Salmonella typhimurium (TA97, TA98, TA100, and TA102). First, relationships were established between their mutagenic activities and either the nature or the position of the substituent on the quinonic nucleus. Compounds substituted in the 2 position were less mutagenic than the 3 isomers. In the second study, the mutagenic properties were compared to the in vitro antitumor activity. Interestingly, some very cytotoxic quinones were only weak mutagens. So where the cytotoxicity is similar, the less mutagenic compounds may be suitable for clinical use as antitumor drugs, in order to avoid important side effects; the Ames test can then be used guide the selection of molecules for further in vivo antitumor screening. It can also be very helpful in selecting the best candidate molecules to be synthesized.
研究了一系列七个在2位或3位被不同基团取代的6-甲基吲哚并[3,2-c]喹啉-1,4-二酮,考察它们在几种浓度下对四株鼠伤寒沙门氏菌(TA97、TA98、TA100和TA102)进行Ames试验时诱导突变的能力。首先,确定了它们的诱变活性与醌核上取代基的性质或位置之间的关系。在2位取代的化合物比3位异构体的诱变性小。在第二项研究中,将诱变特性与体外抗肿瘤活性进行了比较。有趣的是,一些细胞毒性很强的醌类只是弱诱变剂。因此,在细胞毒性相似的情况下,诱变性较小的化合物可能适合作为抗肿瘤药物用于临床,以避免严重的副作用;然后Ames试验可用于指导体内抗肿瘤进一步筛选的分子选择。它在选择要合成的最佳候选分子方面也非常有帮助。